Sally J. Thomas

Sheffield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

JA(c)K-in-the-platelet and M(i)PL fetch PF4.

JA(c)K-in-the-platelet and M(i)PL fetch PF4.

Journal: Blood

Published: January 04, 2024

Heterogeneity of platelets and their responses.

Heterogeneity of platelets and their responses.

Journal: Research and practice in thrombosis and haemostasis

Published: November 18, 2023

Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).

Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).

Journal: British journal of haematology

Published: December 03, 2022

Platelet Heterogeneity in Myeloproliferative Neoplasms.

Platelet Heterogeneity in Myeloproliferative Neoplasms.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: October 07, 2021

Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy.

Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy.

Journal: British journal of cancer

Published: June 07, 2021

Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.

Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.

Journal: British journal of haematology

Published: June 05, 2019

The reversal of anticoagulation in clinical practice .

The reversal of anticoagulation in clinical practice .

Journal: Clinical medicine (London, England)

Published: August 04, 2018

A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability.

A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability.

Journal: Journal of cell science

Published: August 09, 2017

Low-dose methotrexate in myeloproliferative neoplasm models.

Low-dose methotrexate in myeloproliferative neoplasm models.

Journal: Haematologica

Published: May 28, 2017

HPV-negative, but not HPV-positive, oropharyngeal carcinomas induce fibroblasts to support tumour invasion through micro-environmental release of HGF and IL-6.

HPV-negative, but not HPV-positive, oropharyngeal carcinomas induce fibroblasts to support tumour invasion through micro-environmental release of HGF and IL-6.

Journal: Carcinogenesis

Published: March 15, 2017

Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms.

Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms.

Journal: Lancet (London, England)

Published: August 28, 2015

Methotrexate Is a JAK/STAT Pathway Inhibitor.

Methotrexate Is a JAK/STAT Pathway Inhibitor.

Journal: PloS one

Published: January 21, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026